Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seletracetam

Next Previous
Drug Profile

Seletracetam

Alternative Names: UCB 44212

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Oct 2006 Interim results from two phase IIa clinical trials (N01191 and N01192) in patients with epilepsy have been added to the adverse events and Epilepsy therapeutic trials sections
  • 21 Nov 2005 Data presented at the 26th International Epilepsy Congress (IEC-2005) have been added to the Epilepsy and seizure disorders pharmacodynamics section ,,
  • 18 Apr 2005 Data presented at the 9th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2005) have been added to the Parkinson's disease pharmacodynamics section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top